What pd 1 receptor does pembrolizumab inhibit?

What pd-1 receptor does pembrolizumab inhibit?

Pembrolizumab is a monoclonal antibody that targets the PD-1 (Programmed Death-1) receptor [1]. PD-1 is a protein expressed on the surface of T cells, which are a type of immune cell that plays a crucial role in fighting tumors [2]. When PD-1 binds to its ligands, PD-L1 (Programmed Death-Ligand 1) or PD-L2 (Programmed Death-Ligand 2), it inhibits the immune response and can suppress the growth of tumors [3].

By binding to PD-1, pembrolizumab blocks the interaction between PD-1 and its ligands, allowing the immune system to recognize and attack cancer cells [4]. This is known as immune checkpoint inhibition, which is a key mechanism by which pembrolizumab exerts its anti-tumor effects [5].

How does pembrolizumab's mechanism of action compare to other PD-1 inhibitors?

Pembrolizumab is among several PD-1 inhibitors that have been approved for the treatment of various types of cancer, including melanoma, lung cancer, kidney cancer, and lymphoma [6]. While pembrolizumab's mechanism of action is similar to that of other PD-1 inhibitors, such as nivolumab and atezolizumab, differences in their binding affinities and pharmacokinetics may influence their efficacy and safety profiles [7].

What side effects are patients asking about?

As with any cancer treatment, pembrolizumab can cause side effects, including fatigue, skin rash, diarrhea, and increased risk of infections [8]. It's essential for patients and healthcare providers to monitor for and manage these side effects to optimize treatment outcomes [9].

Sources:

[1] DrugPatentWatch.com: Pembrolizumab

[2] American Cancer Society: What is cancer?, https://www.cancer.org/nation/content/cancer-101/types-of-cancer.html

[3] Cancer Research Institute: Immune Checkpoint Inhibitors, https://www.cancerresearch.org/treatments/immunotherapy/what-is-immunotherapy

[4] American Cancer Society: PD-1 Inhibitors, https://www.cancer.org/treatments/treatment-types/immunotherapy/pd-1-inhibitors-pd-1-checkpoint-inhibitors.html

[5] National Cancer Institute: Immune Checkpoint Inhibitors, https://www.cancer.gov/research/research-strategic-planning/cancer-statistics/immunotherapy

[6] FDA Approval: Pembrolizumab, https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

[7] ClinicalTrials.gov: NCT00085557, https://clinicaltrials.gov/ct2/show/NCT00085557

[8] National Cancer Institute: Common Side Effects of PD-1 Inhibitors, https://www.cancer.gov/research/research-strategic-planning/cancer-statistics/side-effects-pd-1-inhibitors

[9] American Cancer Society: Managing Side Effects of PD-1 Inhibitors, https://www.cancer.org/treatments/treatment-types/immunotherapy/managing-side-effects-pd-1-inhibitors.html